This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
LRRC59 / Leucine-rich repeat-containing protein 59 · IHC design guide
Design Immunohistochemistry for LRRC59
Plan LRRC59 chromogenic IHC in paraffin sections with the catalog antibody's 2–5 μg/ml range (datasheet A09874-2). Use the variable cytoplasmic tissue pattern and high staining in placental decidual cells to choose comparison sections (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
LRRC59 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Variable cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining of varying intensity (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A09874-2) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Staining and RNA show medium consistency (HPA tissue IHC) | |
| Regulation | No expression regulator specified (UniProt) | |
| Isoform / epitope | No isoforms; N-terminus processed; cytosolic vs lumenal epitopes (UniProt) |
Section 1
Recommended LRRC59 IHC & IF Protocols
The catalog antibody IHC-P protocol (datasheet: A09874-2) is accompanied by one published colorectal IHC protocol (PMC12576520).
| Sample | Paraffin-embedded human colorectal adenocarcinoma tissue; fixative not specified (datasheet A09874-2) |
| Fixation | Image fixative and duration unreported (datasheet A09874-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A09874-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A09874-2) |
| Primary antibody | Rabbit anti-LRRC59, 2-5 μg/ml (datasheet A09874-2) |
| Primary incubation | Overnight at 4 °C (datasheet A09874-2) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A09874-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | LRRC59-positive staining in glandular cells of appendix (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression of varying intensity in most tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval (datasheet: A09874-2); Tris/EDTA pH 9.0 is a published alternative (PMC12576520).
Section 2
What Is the Expected LRRC59 Staining Pattern?
LRRC59 should appear mainly as cytoplasmic staining of varying intensity across most tissues, with strong staining in selected glandular, neuronal, exocrine glandular, and decidual cells (HPA tissue IHC: Enhanced; medium consistency with RNA). Its endoplasmic reticulum and nuclear envelope localization is consistent with a membrane-associated cytoplasmic pattern (UniProt Q96AG4 localization; transmembrane segment 245–265). Interpret tissue staining against the named cell types, not an entire section’s average intensity.
| Cytoplasmic staining in appendix or duodenal glandular cells, pancreatic exocrine glandular cells, or cortical neurons. | This fits the reported High cell-specific IHC pattern (HPA tissue IHC). Evaluate the named cells within each section; HPA reports varying cytoplasmic intensity across most tissues, so uniform intensity across every cell is not the expected benchmark (HPA tissue IHC). |
| Predominantly nuclear staining, or an isolated plasma-membrane outline, with little cytoplasmic signal. | Treat this as a compartment mismatch and investigate artefact before assigning it to LRRC59. HPA reports cytoplasmic tissue staining and endoplasmic reticulum localization by ICC-IF; UniProt also lists the nuclear envelope, which does not establish diffuse nuclear staining (HPA tissue IHC; HPA subcellular; UniProt Q96AG4 localization). |
| Strong staining in adipocytes, ovarian stromal cells, skeletal myocytes, or smooth muscle cells. | These named populations were not detected in HPA tissue IHC. Check the cell identification and controls, then consider antibody cross-reactivity or endogenous chromogen-generating activity as general IHC explanations. An unexpected positive cell alone does not identify which explanation applies (HPA tissue IHC; general IHC practice). |
| Broad, hazy chromogen deposition that obscures cell boundaries or appears across unrelated compartments. | This is difficult to score as cell-specific LRRC59 staining against HPA’s cytoplasmic pattern. Assess a no-primary control and review blocking, washing, and detection conditions for nonspecific background; those checks are general IHC practice and do not imply a documented LRRC59-specific reagent effect (HPA tissue IHC; general IHC practice). |
| No visible signal in a reported High population, such as appendix glandular cells or pancreatic exocrine glandular cells. | First verify that the named cells are present and that the positive control and detection steps worked (HPA tissue IHC; general IHC practice). A blank section may reflect a technical failure, but HPA’s Enhanced tissue reliability has only medium consistency with RNA, so its staining category is a reference pattern rather than a guarantee for every specimen (HPA tissue IHC). |
💡Expected LRRC59 appearanceCall a positive result when the named HPA-positive cells show predominantly cytoplasmic staining, potentially High in appendix glandular cells or pancreatic exocrine cells; diffuse nuclear signal or strong staining in HPA-undetected adipocytes is suspect (HPA tissue IHC; UniProt Q96AG4 localization).
| Cell type and tissue selection | LRRC59 is widely expressed (UniProt Q96AG4 tissue specificity), but HPA reports variable cytoplasmic IHC intensity. Use a named High population for a positive reference and interpret an undetected population by cell type; neither label describes every cell in that tissue (HPA tissue IHC). |
| Membrane topology and subcellular interpretation | UniProt places residues 1–244 on the cytoplasmic side, a transmembrane segment at 245–265, and residues 266–307 in the lumen (UniProt Q96AG4 topology). These annotations support a membrane-associated pattern, but the supplied evidence gives no antibody epitope location, so topology cannot predict retrieval conditions or epitope accessibility. |
| Antibody validation and limits | HPA lists IHC validation as Enhanced for both HPA030827 and HPA030829; its tissue profile has medium consistency between staining and RNA (HPA antibodies; HPA tissue IHC). This supports comparison with the reported pattern while leaving an unexpected cell or compartment to be checked with controls. |
| IF/ICC: where should LRRC59 appear? | For the separate IF/ICC guide, expect endoplasmic reticulum localization: HPA calls it the enhanced main location and provides images from A-431, U-251MG, and U2OS (HPA subcellular). UniProt also lists the nuclear envelope, whose localization depends on nuclear import machinery including KPNB1 (UniProt Q96AG4 localization). |
| Situation | Likely cause | Next action |
|---|---|---|
| Reported High cells are blank. | The target cell population may be absent from the examined area, or staining and detection may have failed (HPA tissue IHC; general IHC practice). | Confirm the named cell type in the section, inspect a positive-control section, and review the validated IHC workflow’s retrieval, primary incubation, detection, and counterstain steps (general IHC practice). |
| Nuclei dominate the stain. | This conflicts with the reported cytoplasmic IHC pattern; UniProt’s nuclear-envelope annotation does not justify diffuse nuclear staining (HPA tissue IHC; UniProt Q96AG4 localization). | Compare signal with a no-primary control and inspect whether staining tracks the nuclear rim or the whole nucleus; review blocking and detection if control staining persists (general IHC practice). |
| Adipocytes or myocytes stain strongly. | HPA records adipocytes and skeletal and smooth muscle cells as not detected; cross-reactivity or endogenous detection activity is possible (HPA tissue IHC; general IHC practice). | Verify cell identity, compare a no-primary control, and assess endogenous detection activity with controls suited to the chromogenic system (general IHC practice). |
| Background covers both target cells and surrounding tissue. | Nonspecific binding or detection background can obscure the reported cytoplasmic pattern (HPA tissue IHC; general IHC practice). | Check the no-primary control, then review blocking, washes, antibody concentration, and detection conditions as general IHC variables; do not infer LRRC59-specific fixation sensitivity from this pattern. |
| A section shows weak staining where strong staining was expected. | HPA’s High designation applies to specified cell populations, and its Enhanced tissue profile has medium consistency with RNA (HPA tissue IHC). | Score the named cells separately from surrounding tissue and compare a reported High control section processed in the same run (HPA tissue IHC; general IHC practice). |
| A proposed IF pattern disagrees with the IHC slide. | HPA’s ICC-IF result emphasizes the endoplasmic reticulum, while tissue IHC reports cytoplasmic staining; the methods resolve compartments differently (HPA subcellular; HPA tissue IHC; general microscopy practice). | Interpret each result within its own method: assess cytoplasmic cell staining in IHC and endoplasmic reticulum localization on the separate IF/ICC guide (HPA tissue IHC; HPA subcellular). |
Experiment evidence
IHC & IF images showing LRRC59 staining
A09874-2 · IHCIHC analysis of LRRC59 using anti-LRRC59 antibody (A09874-2). LRRC59 was detected in a paraffin-embedded section of human colorectal adenoca
A09874-2 · IHCIHC analysis of LRRC59 using anti-LRRC59 antibody (A09874-2). LRRC59 was detected in a paraffin-embedded section of human lung cancer tissue
A09874-2 · IFIF analysis of LRRC59 using anti-LRRC59 antibody (A09874-2). LRRC59 was detected in an immunocytochemical section of U2OS cells. Enzyme anti
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000108829-LRRC59/tissue/cerebral+cortex#imid_8266059
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000108829-LRRC59/tissue/colon#imid_8265969
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000108829-LRRC59/tissue/liver#imid_8265970
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000108829-LRRC59/tissue/kidney#imid_8265971
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA030827; green = LRRC59, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA030827; green = LRRC59, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for LRRC59 IHC & IF
🧪Run appendix first; its glandular cells should stain (HPA: High in appendix glandular cells). Use adipose tissue adipocytes as the negative comparator (HPA: Not detected in adipocytes); on the appendix slide, non-glandular cells can provide internal contrast, but HPA does not establish them as target-negative, so score them against the adipocyte control and background.
Positive control tissue: Appendix (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show LRRC59 in A-431, U-251MG, U2OS, with annotated localisation: Endoplasmic reticulum (enhanced) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) slide, a host- and class-matched rabbit IgG isotype control, and a validated LRRC59 knockout specimen or peptide-block control if available (caption: rabbit anti-LRRC59; standard IHC practice). Quench endogenous peroxidase and check the appendix slide for DAB background before interpreting glandular staining (caption: HRP/DAB detection; standard IHC practice).
⚠️Feasibility: The selected A09874-2 tissue-IHC caption does not report a fixative, and the supplied evidence reports no LRRC59-specific fixation window or fixation effect (selected-SKU caption). The paraffin-section example uses heat retrieval in EDTA at pH 8.0, but it does not establish that retrieval is required under every condition (selected-SKU caption). ICC-IF images exist for A-431, U-251MG and U2OS, but the evidence does not establish that frozen sections or IF are easier than paraffin IHC; for the appendix slide, endogenous peroxidase can confound DAB interpretation (HPA: subcellular ICC-IF images; standard IHC practice).
HPA tissue IHC evidence for LRRC59
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
| Endometrium | Glandular cells | High | Protein (IHC) | HPA → |
| Hippocampus | Neuronal cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Ovary | Ovarian stroma cells | Not detected | Protein (IHC) | HPA → |
| Skeletal muscle | Myocytes | Not detected | Protein (IHC) | HPA → |
| Smooth muscle | Smooth muscle cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced LRRC59 IHC Tips
Troubleshoot chromogenic LRRC59 staining in paraffin sections using the catalog antibody’s tissue image, expected localisation, and reported tissue patterns (datasheet A09874-2; UniProt Q96AG4; HPA).
What retrieval should I use when LRRC59 staining is weak in paraffin sections?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A09874-2). Keep the retrieval method consistent across a staining run, then compare a weak section with a known positive tissue under the same conditions (standard IHC practice; HPA: high in appendix glandular cells). The catalog image used 2 μg/ml primary antibody overnight at 4°C, so check those incubation conditions before changing retrieval (datasheet A09874-2). If staining remains weak, test an alternative retrieval buffer on matched sections as a fallback and monitor tissue damage and background (standard IHC practice). Score cytoplasmic and perinuclear staining separately when judging improvement (UniProt Q96AG4 localisation; standard IHC practice).
Could fixation explain inconsistent LRRC59 staining across paraffin blocks?
The selected tissue caption describes a paraffin section but does not report its fixative, so LRRC59 sensitivity to fixation is unknown for this antibody (datasheet A09874-2). Compare blocks with documented fixation histories while holding section thickness, EDTA retrieval at pH 8.0, antibody concentration, and detection constant (datasheet A09874-2; standard IHC practice). The catalog image used 2 μg/ml primary antibody overnight at 4°C, providing conditions for that comparison (datasheet A09874-2). Examine morphology alongside staining because damaged sections can make intensity comparisons unreliable (standard IHC practice). Do not attribute a weak block to LRRC59 topology or tissue distribution without a controlled fixation comparison (UniProt Q96AG4 topology; HPA tissue IHC; standard IHC practice).
Is nuclear or diffuse staining plausible for LRRC59 in tissue IHC?
Expect predominantly cytoplasmic staining, with a possible perinuclear pattern, because LRRC59 is reported at the endoplasmic reticulum and nuclear envelope (HPA: cytoplasmic expression in most tissues; UniProt Q96AG4 localisation). Its membrane-spanning segment is at residues 245–265, consistent with a membrane-associated distribution rather than an exclusively soluble nuclear pattern (UniProt Q96AG4 topology). Nuclear-envelope localisation depends on nuclear import machinery including KPNB1, so nuclear-rim staining can warrant closer inspection (UniProt Q96AG4 localisation). If chromogenic signal fills nuclei uniformly, compare an adjacent section without primary antibody and review counterstain intensity before scoring it as LRRC59 (standard IHC practice). Assess glandular cells separately from nearby unstained structures in positive reference tissue (HPA: high in appendix glandular cells; standard IHC practice).
How should epitope position affect interpretation of weak LRRC59 staining?
The supplied record lists 0 annotated isoforms and does not map this antibody’s epitope, so an isoform-specific explanation for weak staining is unsupported (UniProt Q96AG4; datasheet A09874-2). LRRC59 has a cytoplasmic region at residues 1–244, a transmembrane segment at 245–265, and a luminal region at 266–307 (UniProt Q96AG4 topology). Its recorded N-terminal processing and modifications provide possible epitope context, but their effects on this antibody’s IHC staining are unknown (UniProt Q96AG4 processing and modified residues; datasheet A09874-2). Compare matched sections using the documented EDTA retrieval at pH 8.0 before assigning a weak result to epitope masking (datasheet A09874-2; standard IHC practice). Seek antibody epitope information before drawing a region-specific conclusion (standard IHC practice).
How can IF help assess an ambiguous chromogenic LRRC59 pattern?
Use IF on a companion specimen to assess whether the ambiguous IHC pattern overlaps the expected endoplasmic reticulum distribution (HPA subcellular: endoplasmic reticulum; standard IF practice). In multiplex IF, pair LRRC59 with a validated marker for the cell population being assessed, and choose spectrally separated fluorophores with a far-red channel when tissue autofluorescence obscures shorter wavelengths (standard IF practice). Confirm the antibody epitope before choosing permeabilisation: residues 1–244 face the cytoplasm, whereas 266–307 face the lumen (UniProt Q96AG4 topology; standard IF practice). Include single-label and no-primary controls to evaluate bleed-through and background (standard IF practice). Treat IF as a localisation cross-check rather than proof that the catalog antibody has the same performance in both applications (datasheet A09874-2; standard IF practice).
What should I check when LRRC59 DAB staining is widespread?
First distinguish the reported variable cytoplasmic expression from diffuse staining that also covers empty spaces, tissue edges, or the no-primary control (HPA tissue IHC; standard IHC practice). The catalog tissue image used 10% goat serum block, 2 μg/ml primary antibody overnight at 4°C, and a peroxidase-conjugated secondary for 30 minutes at 37°C (datasheet A09874-2). Check primary concentration, blocking, washing, and secondary-only controls while changing one condition at a time (standard IHC practice). Apply an appropriate endogenous-peroxidase block and compare DAB development times across matched sections (standard chromogenic IHC practice). Reassess glandular-cell staining against a no-primary section before treating a uniformly brown field as LRRC59 expression (HPA: high in appendix glandular cells; standard IHC practice).
How should I quantify variable LRRC59 staining across tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the scored cell population and compartment before measuring signal, because reported LRRC59 tissue staining is cytoplasmic and varies in intensity (HPA tissue IHC). For cell-based scoring, record the percentage of cells at intensity 0–3 and calculate an H-score of 0–300; retain the percentage positive as a separate result (standard IHC practice). For spatial measurements, report positive-cell density per mm² of viable tissue within the annotated region (standard IHC practice). Normalise across sections using the same region definition, counterstain threshold, imaging settings, and positive-control tissue (standard IHC practice). Report glandular and stromal populations separately where relevant, since reference staining differs by cell type (HPA: high in appendix glandular cells; HPA: not detected in ovarian stromal cells).
When is an LRRC59-positive IHC result convincing rather than artefactual?
A convincing result follows the expected cytoplasmic or perinuclear distribution and appears in an appropriate cell population, such as glandular cells in the reported positive tissues (UniProt Q96AG4 localisation; HPA tissue IHC). Compare staining with a no-primary section and a reference tissue, recognising that HPA reports Enhanced reliability with medium consistency between staining and RNA expression (HPA tissue IHC; standard IHC practice). Flag uniform nuclear fill, section-edge staining, and necrotic areas for review before counting positive cells (UniProt Q96AG4 localisation; standard IHC practice). Residual endogenous peroxidase can also produce chromogenic signal, so inspect the peroxidase-block control when available (standard chromogenic IHC practice). Interpret focal results by cell type and compartment, rather than by brown area alone (HPA tissue IHC; standard IHC practice).
Boster reagents
Best LRRC59 / Leucine-rich repeat-containing protein 59 IHC Antibodies
A09874-2 has IHC images from human colorectal adenocarcinoma, lung cancer, placenta, and mouse colon paraffin sections, plus IF data from U2OS cells (catalog image captions).
Real IHC data
Anti-LRRC59 Antibody ®
Cat # A09874-2
A09874-2 is listed for IHC in Human, Mouse, and Rat; its IHC captions document human colorectal adenocarcinoma, lung cancer, placenta, and mouse colon paraffin sections (catalog applications, reactivity, and IHC image captions). The same SKU is listed for ICC/IF and has a U2OS cell IF image (catalog applications and IF image caption).
Which to pick: For tissue IHC, choose A09874-2: its own paraffin-section captions document EDTA retrieval at pH 8.0 and 2 μg/ml primary antibody; the fixative is unreported (catalog IHC image captions). For IF/ICC, A09874-2 has a U2OS cell IF image using 5 μg/ml primary antibody (catalog IF image caption). For work across species, A09874-2 lists Human, Mouse, and Rat reactivity, while its IHC images document Human and Mouse samples; clonality is unreported (catalog reactivity, IHC image captions, and clone field).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q96AG4 (LRC59_HUMAN, Leucine-rich repeat-containing protein 59).
- Human Protein Atlas. LRRC59 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. LRRC59 subcellular location (ICC-IF): Localized to the endoplasmic reticulum..
- Human Protein Atlas. LRRC59 antibody validation summary (2 antibodies).
- Construction of a prognostic model for colorectal adenocarcinoma based on Zn transport-related genes identified by single-cell sequencing and weighted co-expression network analysis. Frontiers in oncology 2023 — PMC10565862.
- Overexpression of LRRC59 Is Associated with Poor Prognosis and Promotes Cell Proliferation and Invasion in Lung Adenocarcinoma. OncoTargets and therapy 2020 — PMC7342457.
- LRRC59 inhibits perk pathway‑induced apoptosis and promotes cell proliferation, migration and invasion in colorectal cancer cells. Oncology reports 2026 — PMC12576520.
- Pan-cancer analysis of LRRC59 with a focus on prognostic and immunological roles in hepatocellular carcinoma. Aging 2024 — PMC11131990.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:11964394 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for LRRC59 (Leucine-rich repeat-containing protein 59). Expected localisation Variable cytoplasmic staining in most tissues (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A09874-2). Validated IHC antibody: A09874-2 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human colorectal adenocarcinoma tissue; fixative not specified (datasheet A09874-2); 2. Fixation: Image fixative and duration unreported (datasheet A09874-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A09874-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A09874-2); 8. Primary antibody: Rabbit anti-LRRC59, 2-5 μg/ml (datasheet A09874-2); 9. Primary incubation: Overnight at 4 °C (datasheet A09874-2). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Staining and RNA show medium consistency (HPA tissue IHC); Isoform / epitope: No isoforms; N-terminus processed; cytosolic vs lumenal epitopes (UniProt); Regulation: No expression regulator specified (UniProt). Evidence: UniProt Q96AG4, HPA tissue IHC · Enhanced, HPA ICC-IF · endoplasmic reticulum., Datasheet A09874-2, PMC12576520. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/LRRC59/immunohistochemistry-ihc-guide.